Trials Near Add Your Location

Accepting patients

Cabozantinib

A Phase II Study of Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or AXL Activity
Learn more
  • Tyrosine Kinase (TK) Inhibitor
  • Phase 2
  • Has results

Accepting patients

TAPUR

Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer (TAPUR)
Learn more
  • Phase 2
All clinical trials have eligibility criteria - or a list of reasons why you may be able or unable to participate in a trial. Answer a few questions to view your personalized results - all in under 60 seconds.
Help me find trials

Accepting patients

CARE Study

A Phase 1/2, Open-Label, Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity Study of Repotrectinib in Pediatric and Young Adult Subjects With Advanced or Metastatic Malignancies Harboring ALK, ROS1, NTRK1-3 Alterations
Learn more
  • Tyrosine Kinase (TK) Inhibitor
  • Phase 1/2
  • Has results

Accepting patients

Larotrectinib

A Phase II Basket Study of the Oral TRK Inhibitor Larotrectinib (BAY2757556) in Subjects With NTRK Amplification Positive and Pan-TRK Positive Tumors
Learn more
  • Tyrosine Kinase (TK) Inhibitor
  • Phase 2

Accepting patients

Genomically-Guided Treatment Trial in Brain Metastases
Learn more
  • PI3K Inhibitor
  • Tyrosine Kinase (TK) Inhibitor
  • Phase 2

Accepting patients

TRIDENT-1

A Phase 1/2, Open-Label, Multi-Center, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of TPX-0005 in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1)
Learn more
  • Tyrosine Kinase (TK) Inhibitor
  • Phase 1/2
  • Has results

Accepting patients

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol
Learn more
  • Phase 2

Accepting patients

NAUTIKA1: Multicenter, Phase II, Neoadjuvant and Adjuvant Study of Multiple Therapies in Biomarker-Selected Patients With Resectable Stages IB-III Non-Small Cell Lung Cancer
Learn more
  • Phase 2

Accepting patients

Tumor-Agnostic Precision Immunooncology and Somatic Targeting Rational for You (TAPISTRY) Phase II Platform Trial
Learn more
  • Phase 2

Accepting patients

Larotrectinib to Enhance RAI Avidity in Patients With Differentiated Thyroid Cancer Harboring NTRK Fusions
Learn more
  • Radiation
  • Tyrosine Kinase (TK) Inhibitor
  • Phase 2